Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD)
Biosimilars are increasingly used in patients with inflammatory bowel diseases (IBD) as a cost-effective alternative option to the reference biologics that have gone off-patent –i.e. infliximab, adalimumab [1]. Their approval in IBD therapy in 2013 immediately gave rise to many concerns about immunogenicity, safety, and efficacy [2–4]. The greatest fear concerned the extrapolation of the indication to IBD from studies performed in other inflammatory diseases [3,4]. In the following years, an increasing number of clinical trials have gradually shown that biosimilars can be considered to be as safe and efficacious as the originator [5].
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Angelo Viscido, Andrea Buda, Flavio Caprioli, Mariabeatrice Principi, Marco Daperno, Alessandro Armuzzi Tags: Correspondence Source Type: research
More News: Clinical Trials | Gastroenterology | Humira | Inflammatory Bowel Disease | Italy Health | Liver | Liver Disease | Remicade | Study | Urology & Nephrology